Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Opko Health Inc (OPK)

Opko Health Inc (OPK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Financial Summary for [[ item.sessionDateDisplayLong ]]
OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.

Fiscal Year End Date: 12/31

(Values in U.S. Thousands) Dec, 2023 Dec, 2022 Dec, 2021 Dec, 2020 Dec, 2019
Sales 863,500 1,004,200 1,774,720 1,435,410 901,940
Sales Growth -14.01% -43.42% +23.64% +59.15% -8.92%
Net Income -188,860 -328,410 -30,140 30,590 -314,930
Net Income Growth +42.49% -989.62% -198.53% +109.71% -105.78%
(Values in U.S. Thousands) Dec, 2023 Dec, 2022 Dec, 2021 Dec, 2020 Dec, 2019
Total Assets 2,011,700 2,167,260 2,399,720 2,473,060 2,309,270
Total Assets Growth -7.18% -9.69% -2.97% +7.09% -5.79%
Total Liabilities 622,480 605,610 714,590 801,510 694,510
Total Liabilities Growth +2.79% -15.25% -10.84% +15.41% +5.26%
(Values in U.S. Thousands) Dec, 2023 Dec, 2022 Dec, 2021 Dec, 2020 Dec, 2019
Operating Cash Flow -28,200 -95,190 38,340 39,480 -172,520
Operating Cash Flow Growth +70.38% -348.28% -2.89% +122.88% -58.07%
Net Cash Flow -57,310 18,480 62,500 -13,240 -11,020
Change in Net Cash Flow -410.12% -70.43% +572.05% -20.15% -321.73%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar